Genprex Inc (NASDAQ:GNPX) (FRA:2DE) CEO Rodney Varner tells Proactive the group is gearing up to enroll patients in its Acclaim-1 clinical trial evaluating its lead drug candidate REQORSA in combination with AstraZeneca PLC’s (LON:AZN) (NASDAQ:AZN) Tagrisso (osimertinib) for late-stage non-small cell lung cancer following a review from regulator the FDA.
The latter has reviewed and confirmed that all comments have been addressed regarding the protocol for the trial, which is an open-label, multi-center Phase 1/2 study testing the drug combined with Tagrisso in those whose disease has progressed after treatment with Tagrisso.